Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 121

Sort by

Sort Order Select

Journal Articles

Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia

Mohd Minhajuddin, Amanda C. Winters, Marc Schwartz, Daniel A. Pollyea, Craig T Jordan

Blood (2022) 140 (Supplement 1): 5986–5987.

https://doi.org/10.1182/blood-2022-169167

Published: 2022

Journal Articles

Targeting Microenvironmental Signals in Myeloid Malignancies

Benjamin Rodems, Sonali Sharma, Takashi Ito, Craig T Jordan, Michael W. Becker, Laura M. Calvi, John M. Ashton, Jeevisha Bajaj

Blood (2022) 140 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2022-163601

Published: 2022

Journal Articles

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Blood (2022) 140 (Supplement 1): 3275–3276.

https://doi.org/10.1182/blood-2022-157802

Published: 2022

Journal Articles

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Alexander Hayden, Grace Bosma, Jonathan A. Gutman, Maria L. Amaya, Diana Abbott, Clayton Smith, Brett M. Stevens, Craig T. Jordan, Daniel A. Pollyea, Christine M. McMahon

Blood (2022) 140 (Supplement 1): 9163–9164.

https://doi.org/10.1182/blood-2022-171064

Published: 2022

Journal Articles

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Christine M. McMahon, Kellen Gil, Maria L. Amaya, Jonathan A. Gutman, Alexander Hayden, Marc Schwartz, Grace Bosma, Diana Abbott, Brett M. Stevens, Clayton Smith, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6185–6186.

https://doi.org/10.1182/blood-2022-170168

Published: 2022

Journal Articles

Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells

Anagha Inguva, Krysta L. Engel, Hunter Tolison, Mark J Althoff, Shanshan Pei, Maria L. Amaya, Anna Krug, Mohammad Minhajuddin, Courtney L Jones, Austin E. Gillen, Monica Ransom, Sarah Staggs, Daniel A. Pollyea, Clayton Smith, Brett M. Stevens, Craig T. Jordan

Blood (2022) 140 (Supplement 1): 5922–5923.

https://doi.org/10.1182/blood-2022-167787

Published: 2022

Journal Articles

Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens

Mohd Minhajuddin, Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Nicholas Miltgen, Ji Yuan, Amy Treece, Jonathan A. Gutman, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6274–6275.

https://doi.org/10.1182/blood-2022-167856

Published: 2022

Journal Articles

The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation

Maria L. Amaya, Anagha Inguva, Shanshan Pei, Courtney Jones, Anna Krug, Haobin Ye, Mohammad Minhajuddin, Amanda Winters, Steffanie L. Furtek, Fabia Gamboni, Brett Stevens, Angelo D’Alessandro, Daniel A. Pollyea, Philip Reigan, Craig T. Jordan

Blood (2022) 139 (4): 584–596.

https://doi.org/10.1182/blood.2021013201

Published: 2022

Includes: Supplemental data

Journal Articles

Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia

Mohd Minhajuddin, Haobin Ye, Amanda C. Winters, Shanshan Pei, Nabilah Khan, Brett M. Stevens, Biniam Adane, Maria L. Amaya, Anagha Inguva, Anna Krug, Maura Gasparetto, Daniel W. Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T. Jordan

Blood (2021) 138 (Supplement 1): 630.

https://doi.org/10.1182/blood-2021-151400

Published: 2021

Journal Articles

Unique Metabolic Vulnerabilities of Myelodysplastic Syndrome Stem Cells

Brett M. Stevens, Krysta L. Engel, Austin E. Gillen, Rachel Culp-Hill, Angelo Dalessandro, Scott Alper, Daniel A. Pollyea, Craig T. Jordan

Blood (2021) 138 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2021-150749

Published: 2021

Journal Articles

Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies

Brett M. Stevens, Amanda C. Winters, Mohammad Minhajuddin, Maria L. Amaya, Christine M. McMahon, Jonathan A. Gutman, Clayton Smith, Deng Wang, Connor Adkins, Olivia Ondracek, Craig T. Jordan, Daniel A. Pollyea

Blood (2021) 138 (Supplement 1): 2612.

https://doi.org/10.1182/blood-2021-150824

Published: 2021

Journal Articles

IL-1 Via IRAK1/4 Sustains Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse

Tzu-Chieh Ho, Hiroki Kawano, Mark W. LaMere, Naxin Guo, Yu-Chiao Chiu, Jian Wang, Craig T. Jordan, Nikolay V. Dokholyan, Laura M. Calvi, Rakesh Kumar Singh, Michael W. Becker

Blood (2021) 138 (Supplement 1): 1175.

https://doi.org/10.1182/blood-2021-149903

Published: 2021

Journal Articles

Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy

Amanda C. Winters, Grace Bosma, Diana Abbott, Mohd Minhajuddin, Craig T Jordan, Daniel A. Pollyea, Jonathan A. Gutman

Blood (2021) 138 (Supplement 1): 3957.

https://doi.org/10.1182/blood-2021-154392

Published: 2021

Journal Articles

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-138821

Published: 2020

Journal Articles

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Andrew Kent, MD PhD, Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138832

Published: 2020

Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-136120

Published: 2020

Journal Articles

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

Courtney L Jones, PhD, Brett M. Stevens, PhD, Rachel Culp-Hill, BS, Angelo Dalessandro, PhD, Anna Krug, BS, Madeline Goosman, Shanshan Pei, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2019) 134 (Supplement_1): 1272.

https://doi.org/10.1182/blood-2019-125773

Published: 2019

Journal Articles

STAT3 Plays a Critical Role in Mitochondrial Function and Survival of Primary AML Cells

Maria L Amaya, MD PhD, Anagha Inguva, BSc, Courtney L Jones, PhD, Anna Krug, BS, Shanshan Pei, PhD, Phillip Reigan, PhD, Craig T Jordan, PhD

Blood (2019) 134 (Supplement_1): 1275.

https://doi.org/10.1182/blood-2019-127669

Published: 2019

Journal Articles

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

James Chavez, BS, Jennifer L Rabe, BS, BA, Kelly Higa, MS, Dirk Loeffler, Ahmed Nouraiz, PhD, Taylor Mills, BA, Beau M Idler, Brett M. Stevens, PhD, Courtney Fleenor, PhD, Claus Nerlov, PhD, Hideaki Nakajima, MD, James Hagman, Timm Schroeder, PhD, Hyun Min Kim, PhD, Craig T Jordan, PhD, James DeGregori, Eric Pietras, PhD

Blood (2019) 134 (Supplement_1): 822.

https://doi.org/10.1182/blood-2019-129300

Published: 2019

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

NARROW

Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia

Targeting Microenvironmental Signals in Myeloid Malignancies

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells

Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens

The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation

Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia

Unique Metabolic Vulnerabilities of Myelodysplastic Syndrome Stem Cells

Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies

IL-1 Via IRAK1/4 Sustains Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse

Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

STAT3 Plays a Critical Role in Mitochondrial Function and Survival of Primary AML Cells

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only